This month, Augmenix has launched SpaceOAR.jp; a Japanese language website dedicated to providing clinicians more information on prostate-rectum spacing with SpaceOAR® hydrogel and the proven benefits it offers to men with prostate cancer. The new website supports the opening of Augmenix K.K. headquarters in Tokyo, Japan, followed by the recent announcement that SpaceOAR hydrogel is now available to all prostate cancer radiotherapy patients in Japan through the Ministry of Health, Labour & Welfare (MHLW) national reimbursement.
Stephen J. McGill, Vice President and General Manager, International stated “The launch of SpaceOAR.jp adds to the list of several exciting developments from our team in Japan over the past few months. This native language website is another sign of our commitment to provide the highest levels of support for SpaceOAR. It will work in tandem with our Japanese Clinical Specialist Team to ensure clinicians have access to key product information, best practise application and clinical data for SpaceOAR hydrogel.
Yoshi Kuratani, General Manager of Japan, continued to emphasise, “Many Japanese clinicians have expressed interest in SpaceOAR hydrogel and SpaceOAR.jp allows them to learn more about how the technology works along with how it can help enable the advancement of radiotherapy. It is our goal to make minimally invasive, prostate-rectum spacing the standard of care for all men undergoing radiation therapy.”Visit Spaceoar.jp For More Information
SpaceOAR hydrogel is available nationally in Japan under the Reimbursement Category: ‘200 Bioabsorbable material for Radiation Therapy’.